Company profile: ClearNote Health
1.1 - Company Overview
Company description
- Provider of cancer detection solutions, including the Avantect Pancreatic Cancer Test—a blood test that detects pancreatic cancer in its earliest stages by measuring the biomarker 5hmC; the Virtuoso Epigenomics Platform—a whole genome sequencing and 5hmC enrichment solution for revealing active disease biology for drug discovery and development; and targeted multi-cancer panels that track epigenomic signals via a single blood draw.
Products and services
- Avantect Pancreatic Cancer Test: Blood-based assay that detects pancreatic cancer in its earliest stages by measuring 5-hydroxymethylcytosine (5hmC) levels in blood samples, enabling early epigenomic detection
- Targeted Multi-Cancer Panels: Single-blood-draw assays that track epigenomic signals to detect several distinct cancers concurrently, consolidating testing into one visit for streamlined, multi-cancer screening
- Virtuoso Epigenomics Platform: Whole-genome-scale system that couples sequencing with 5hmC enrichment to reveal active disease biology, supporting drug discovery and development with epigenomic readouts
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ClearNote Health
Lucid Diagnostics
HQ: United States
Website
- Description: Provider of non-invasive, office-based diagnostic solutions for detecting Barrett's esophagus and esophageal adenocarcinoma, including EsoGuard, a DNA test using targeted next-generation sequencing to detect abnormal esophageal cells, and EsoCheck, a non-endoscopic swallowable capsule device that collects esophageal cells for analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lucid Diagnostics company profile →
Miroculus
HQ: United States
Website
- Description: Provider of hands-off sample-to-answer solutions for molecular testing, delivering assay flexibility and automation via an affordable digital microfluidics platform that enables seamless workflow integration from novel molecular protocols to data analytics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Miroculus company profile →
Ayala Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage small molecule therapeutics, including gamma secretase inhibitors that block Notch-pathway activation. Pipeline includes AL101 in Phase 2 for recurrent/metastatic adenoid cystic carcinoma and AL102 in Phase 2/3 for desmoid tumors, with a planned Phase 2 in relapsed/refractory T-cell acute lymphoblastic leukemia. Conducts clinical trials to evaluate safety and efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ayala Pharmaceuticals company profile →
Enara Bio
HQ: United Kingdom
Website
- Description: Provider of cancer immunotherapy solutions targeting the T-cell/cancer cell interface, offering the EDAPT platform to discover cancer-specific Dark Antigens, TCR-directed immunotherapies, and off-the-shelf therapeutic cancer vaccines targeting multiple Dark Antigens for broad patient populations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enara Bio company profile →
Fate Therapeutics
HQ: United States
Website
- Description: Provider of iPSC-derived cellular therapeutics and platform technologies, offering a proprietary clonal master iPSC platform for off-the-shelf therapies; CAR T and CAR NK candidates including FT819 (CD19 for systemic lupus erythematosus and other autoimmune diseases), FT522 (CAR NK with alloimmune defense receptor for B-cell lymphoma and autoimmune diseases), FT825 (HER2 solid tumors), plus NK and T-cell programs for cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fate Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ClearNote Health
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ClearNote Health
2.2 - Growth funds investing in similar companies to ClearNote Health
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ClearNote Health
4.2 - Public trading comparable groups for ClearNote Health
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →